Protalix BioTherapeutics, Inc.

Total Valuation

Protalix BioTherapeutics, Inc. carries a market capitalization of 185.31M, placing it among publicly traded companies globally. Its enterprise value stands at 129.40M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Protalix BioTherapeutics, Inc. currently has 80.57M shares outstanding.

Valuation Ratios

Protalix BioTherapeutics, Inc. trades at a trailing price-to-earnings ratio of 11.22. The price-to-sales ratio is 2.25, and the price-to-book ratio stands at -0.47.

Enterprise Valuation

On an enterprise value basis, Protalix BioTherapeutics, Inc. trades at an EV/EBITDA multiple of 6.07 and an EV/FCF ratio of 7.03. The EV/Sales ratio of 1.69 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 6.54 provides insight into valuation relative to core operating earnings.

Financial Position

Protalix BioTherapeutics, Inc. maintains a current ratio of 3.15, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 12.62, indicating elevated leverage, while an interest coverage ratio of 13.85 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Protalix BioTherapeutics, Inc. has paid 3.93M in income taxes, reflecting an effective tax rate of 20.42.

Stock Price Statistics

Protalix BioTherapeutics, Inc.'s stock has gained approximately 56.46259% over the past 52 weeks. The 50-day moving average sits at 2.08, while the 200-day moving average is 2.20.

Income Statement

Over the trailing twelve months, Protalix BioTherapeutics, Inc. generated 76.38M in revenue and converted that into 15.33M in net income, yielding earnings per share of 0.19. EBITDA reached 21.31M, while operating income came in at 19.79M.

Balance Sheet

Protalix BioTherapeutics, Inc. holds 51.08M in cash and equivalents against 8.48M in total debt, resulting in a net debt position of -41.00M. Total book value stands at -366.60M, with working capital of 58.97M providing operational flexibility.

Cash Flow

Protalix BioTherapeutics, Inc. produced 15.09M in operating cash flow over the past twelve months. After subtracting -2.09M in capital expenditures, free cash flow totaled 13.00M - equivalent to 0.16 per share.

Margins

Protalix BioTherapeutics, Inc. operates with a gross margin of 69.97, reflecting its pricing power and cost economics. The operating margin of 25.91 and net profit margin of 20.07 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Protalix BioTherapeutics, Inc.'s most recent stock split took place on December 20, 2019 with a 10:1 split ratio.